Trilogy Medicinal

Closed
yelp logo

(2)

Photos

264 NW Peacock Blvd Ste 103
Port Saint Lucie, FL 34986

Trilogy Medicinal is a leading medical marijuana certification office in Port St. Lucie, Florida, offering state-required recommendations for patients seeking access to medical cannabis. With a team of state-certified physicians, they provide quick and easy evaluations, ensuring patients receive the necessary documentation to legally purchase and possess medical marijuana.

As a trusted provider, Trilogy Medicinal offers a range of services, including new patient consultations, transfer consultations, and re-certification consultations, all of which include dosage adjustments and unlimited support. With their expertise and commitment to patient care, Trilogy Medicinal aims to provide easy access, cost savings, and legal protection for individuals seeking the benefits of medical cannabis.

Generated from the website

Reviews

yelp logo
3.0

(2)

Photo of Tim M.
Tim M.
7/13/2022

Process was great, good interaction with Staff and Doctor who answered all my questions, provided me with easy to follow instructions, and was out the door in 30 minutes.

Bakr K.
12/6/2023

Worse place ever. No appointments and the doctor is always out of town. I would give them a zero star if I could. Very unprofessional

Own this business?
See a problem?

You might also like

Addiction Alternatives
Community development groups, Psychiatrists and psychoanalysts, Internal medicine practitioners

Addiction Alternatives

About Us Addiction Alternatives is a comprehensive outpatient program primarily intended to transition patients from dependence on opiate medications to a therapeutic alternative such a buprenorphine (Suboxone, *Sebutex). Patients are medical evaluated then placed on a detoxification schedule for buprenorphine. Adjunctive medications are prescribed to assist in the transition process. This phase is a called induction and may last 2-7 days. The next step is called stabilization as the cravings and withdrawal symptoms subside and the patient reaches a comfortable maintenance dosage of buprenorphine. Subsequently, the patient is given a taper schedule for buprenorphine, intended to allow reduction and eventual discontinuation of the medication without a relapse into opiate use or dependence. While the duration of the entire process varies from individual to individual, it usually requires about six months in the well-motivated patient. While the above process is evolving, the patient is directed to attend 12 Step models of outpatient rehabilitation meetings at AA and NA meetings. These are imperative as patients require psychologic adjustment to a drug-free and abstinent existence when the buprenorphine is eventually discontinued. Serial urine monitoring will occur at visits in the office, and randomly as well, to ensure compliance with the therapeutic contract which is signed upon entry to the practice. Patients utilizing illicit or unprescribed medications will be excluded from future participation. All patients are given reading materials to foster education regarding opioid dependence and abuse. There is an extensive support system available and questions are addressed seven days a week telephonically or in person. While the primary purpose of the practice is opioid detoxification and rehabilitation, there is also treatment of alcohol dependence with naltrexone HCL (Vivitrol) with intramuscular injections of the medication, AA meetings, education, and urine monitoring. Naltrexone was also approved for maintenance treatment of opioid dependence in 2010. Another maintenance agent utilized for alcohol dependence is acamprosate sodium (* Campral). Patients who are substance dependent often times have underlying co-occurring psychiatric symptoms which interfere with rehabilitation and exacerbate symptoms of anxiety, depression, and mood dysregulation. This psychiatric component is evaluated and treated contemporaneously with the rehabilitation process, utilizing psychotropic medication and psychotherapy.
United StatesFloridaPort Saint LucieTrilogy Medicinal

Partial Data by Infogroup (c) 2026. All rights reserved.